Eyecheck Announces FDA IND Clearance of STRI Formula, the First-Ever Food-Based, Combination Product in the STRI Phase 2 Clinical Trial for COVID-19 Symptoms

Chicago, IL, November 04, 2021 –(PR.com)– Eyecheck, Inc. today announced the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate STRI Formula in non-hospitalized adults with COVID-19 in the Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial (clinicaltrials.gov NCT05046561). STRI Formula is a combination of nine food-based ingredients that have been shown to display immunosupportive effects in controlled laboratory experiments. The IND is active, and Eyecheck intends to initiate the trial in November 2021.

“COVID-19 continues to be a significant cause of morbidity and mortality in the United States and throughout the world. We hope that STRI Formula will help individuals in the STRI Phase 2 Clinical Trial experience relief from COVID-19 symptoms more quickly,” said Rama D. Jager, MD, Founder and Chief Medical Officer.

“At Eyecheck, our mission is to utilize evidenced-based nutrition for everyday health. STRI Formula has been specifically formulated as a food-based regimen to help individuals with COVID-19 in the STRI Phase 2 Clinical Trial. We are excited to launch the trial and investigate the potential of STRI Formula for COVID-19 symptom management,” stated J. Anthony Moses, CEO.

About the STRI Phase 2 Clinical Trial

The STRI Phase 2 Clinical Trial is an IRB-approved, randomized, double-blind, placebo-controlled clinical trial sponsored by Eyecheck, Inc. and conducted by Beat COVID LLC. The primary endpoint in the STRI Phase 2 Clinical Trial is the length of time to initial meaningful clinical improvement in COVID-19 symptoms. Secondary endpoints of the STRI Phase 2 Clinical Trial include an assessment of rates of hospitalization, fever, and hypoxia. Eyecheck hopes that STRI Formula will help people with COVID-19 get better faster. For further information regarding the STRI Phase 2 Clinical Trial, please visit https://beatcovidtrial.com.

About Eyecheck

Eyecheck is a company dedicated to offering physician-formulated, clinically-validated, and independently-certified premium products to support everyday health. Eyecheck’s products are meticulously formulated using evidence-based research from peer-reviewed reports of clinical studies to help support, maintain, and improve people’s health. For further information on Eyecheck, please visit https://eyecheck.com.

About Beat COVID

Beat COVID is a group of leading physician-scientists, clinical researchers and doctors working together to try to slow the spread of COVID-19. Our mission is simple: We are trying to flatten the curve. For further information regarding Beat COVID, please visit https://beatcovidtrial.com.

About COVID-19

Starting in December 2019, a novel coronavirus designated SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), spread via close contact, respiratory droplets, and aerosols, has caused an international pandemic of respiratory illness termed COVID-19. COVID-19 ranges from a mild, self-limiting respiratory disease to severe progressive pneumonia, multiorgan failure, and death.

Beat COVID LLC (https://beatcovidtrial.com)

Principal Investigator
Rama D. Jager, MD, MBA, FACS

Clinical Trial Manager
Ambika Sharma, BS

Clinical Trial Coordinators
Taron D. Asatryan, BSLAS

Melissa Ruelas, BHS, CCMA